These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36170792)

  • 21. In vitro activity of tedizolid and comparator agents against clinical Gram-positive isolates recovered from patients with cancer.
    Rolston KVI; Reitzel R; Vargas-Cruz N; Shelburne SA; Raad II; Prince RA
    Diagn Microbiol Infect Dis; 2018 Aug; 91(4):351-353. PubMed ID: 29661529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia.
    Chen KH; Huang YT; Liao CH; Sheng WH; Hsueh PR
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6262-5. PubMed ID: 26248355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone.
    Zurenko G; Bien P; Bensaci M; Patel HN; Thorne G
    Ann Clin Microbiol Antimicrob; 2014 Sep; 13():46. PubMed ID: 25238753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America.
    Sader HS; Flamm RK; Streit JM; Carvalhaes CG; Mendes RE
    Int J Infect Dis; 2018 Dec; 77():82-86. PubMed ID: 30315990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of
    Choudhury S; Mun LK; Xuan ENC; Jia LS; Vasoo S; Wickramasinghe SS; Mee LJ
    J Clin Pathol; 2019 Feb; 72(2):181-184. PubMed ID: 30446512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).
    Duncan LR; Sader HS; Smart JI; Flamm RK; Mendes RE
    J Glob Antimicrob Resist; 2017 Sep; 10():271-276. PubMed ID: 28735051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China.
    Li S; Guo Y; Zhao C; Chen H; Hu B; Chu Y; Zhang Z; Hu Y; Liu Z; Du Y; Gui Q; Ji P; Zeng J; Cao B; Fu Q; Zhang R; Wang Z; Zhuo C; Feng X; Jia W; Jin Y; Xu X; Liao K; Ni Y; Yu Y; Xu X; Hu Z; Lei JE; Yang Q; Wang H
    J Med Microbiol; 2016 Oct; 65(10):1215-1224. PubMed ID: 27599998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011).
    Sader HS; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2013 Apr; 75(4):417-22. PubMed ID: 23514757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).
    Sader HS; Streit JM; Fritsche TR; Jones RN
    Clin Microbiol Infect; 2006 Sep; 12(9):844-52. PubMed ID: 16882289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of tedizolid against clinical isolates of Staphylococcus lugdunensis and Staphylococcus haemolyticus from Europe and the United States.
    Farrell DJ; Mendes RE; Bensaci M
    Diagn Microbiol Infect Dis; 2019 Jan; 93(1):85-88. PubMed ID: 30314652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Five-year analysis of the
    Carvalhaes CG; Sader HS; Streit JM; Mendes RE
    JAC Antimicrob Resist; 2022 Oct; 4(5):dlac088. PubMed ID: 36072303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
    Zhang Z; Chen M; Yu Y; Pan S; Liu Y
    Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries.
    Pfaller MA; Mendes RE; Streit JM; Hogan PA; Flamm RK
    J Antimicrob Chemother; 2017 Nov; 72(11):3093-3099. PubMed ID: 28961701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group.
    Pfaller MA; Jones RN; Doern GV; Sader HS; Kugler KC; Beach ML
    Diagn Microbiol Infect Dis; 1999 Apr; 33(4):283-97. PubMed ID: 10212756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.
    Mutnick AH; Biedenbach DJ; Turnidge JD; Jones RN
    Diagn Microbiol Infect Dis; 2002 May; 43(1):65-73. PubMed ID: 12052631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
    Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
    Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).
    Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
    J Antimicrob Chemother; 2015 Feb; 70(2):498-504. PubMed ID: 25362568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010-2019).
    Sader HS; Carvalhaes CG; Mendes RE
    Int J Infect Dis; 2021 Jan; 102():524-528. PubMed ID: 33207274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.
    Prokocimer P; Bien P; Deanda C; Pillar CM; Bartizal K
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4608-13. PubMed ID: 22687509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.